Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Moolec Science SA files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
Revenue
0.91
5.63
Cost of revenue
1.05
5.15
Gross profit
-0.14
0.47
Research and development
0.99
1.35
1.77
Selling, general and administrative
0.02
0.11
General and administrative
2.52
4.81
7.52
Operating income
-3.65
-6.65
-9.04
Interest expense
0
0.16
1.17
Pre-tax income
-4.53
-52
-8.36
Income tax
-0.23
-1.05
Net income
-4.53
-51.8
-7.31
EBITDA
-6.63
EPS, basic
-0.15
-1.50
-0.19
EPS, diluted
-0.15
-1.50
-0.19
Balance sheet
FY2023
FY2023
FY2024
Cash and equivalents
1.08
2.53
5.39
Short-term investments
0.31
Receivables
1.33
1.01
Inventory
0.47
6.28
Total current assets
1.08
5.33
13.7
Property, plant and equipment
0.01
1.14
Lease right-of-use assets
0.04
0.44
Goodwill
0.25
0.26
Intangible assets
4.6
8.52
8.98
Total assets
5.69
24.1
34.8
Accounts payable
1.23
7.48
3.41
Total current liabilities
4.09
12.6
8.15
Lease liabilities
0.25
Total liabilities
4.09
13.9
28
Paid-in capital
7.29
67
69.2
Retained earnings
-6.83
-58.6
-65.9
Total equity
1.6
10.1
6.82
Total liabilities and equity
5.69
24.1
34.8
Cash flow statement
FY2023
FY2023
FY2024
Net income
-4.53
-51.8
-7.31
Depreciation and amortization
0.02
Cash from operations
-1.89
-7.51
-9.33
Capital expenditures
-0.01
-0.16
Cash from investing
-2.34
0.13
Debt issued
2.17
2.59
Debt repaid
-0.88
-2.51
Stock issued
0.01
2.17
Cash from financing
2
11.3
11.7
Exchange rate effect
-0.01
0.01
Net change in cash
0.11
1.43
2.52
Free cash flow
-7.53
-9.49
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $5.60 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
8.4%
Gross profit / revenue.
Operating margin
-160.8%
Operating income / revenue.
Pre-tax margin
-148.6%
Pre-tax income / revenue.
Net margin
-130.0%
Net income / revenue.
FCF margin
-168.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-165.8%
Cash from operations / revenue.
Return on assets (ROA)
-24.9%
Net income / average total assets.
R&D / revenue
31.5%
Research and development expense / revenue.
Capex / revenue
2.8%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
521.5%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
44.6%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.69x
Current assets / current liabilities.
Quick ratio
0.79x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.66x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
80.4%
Total liabilities / total assets.
Interest coverage
-7.76x
Operating income / interest expense.
Working capital
$5.6M
Current assets - current liabilities.
Goodwill and intangibles / assets
26.6%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.19x
Revenue / average total assets.
Inventory turnover
1.53x
Cost of revenue / average inventory.
Days inventory
239 days
365 x average inventory / cost of revenue.
Receivables turnover
4.81x
Revenue / average receivables.
Days sales outstanding
76 days
365 x average receivables / revenue.
Days payables
386 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-71 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.19
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.19
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$4.1M
Share price x shares outstanding.
Enterprise value
-$1.3M
Market cap + total debt - cash - short-term investments.
P/S
0.72x
Market cap / revenue.
FCF yield
-233.3%
Free cash flow / market cap.
Earnings yield
-179.8%
Net income / market cap (the inverse of P/E).
What was Moolec Science SA's revenue in fiscal 2024?
Moolec Science SA reported revenue of $5.6M for fiscal 2024, 521.5% higher than the year before.
Was Moolec Science SA profitable in fiscal 2024?
No. It reported a net loss of $7.3M.
How much free cash flow did Moolec Science SA generate in fiscal 2024?
Cash from operations of $9.3M minus capital expenditures of $158.3K left free cash flow of -$9.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.